BioCryst Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 89   

Articles published

BCRX 9.36 +0.07 (0.75%)
price chart
Why BioCryst Pharmaceuticals, Inc. Shares Scorched Higher
What: Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX ) , a predominantly clinical-stage biotech company focused on developing novel small molecule drugs to treat varying diseases, scorched higher by as much as 12% in Wednesday's trading session ...
Ebola Finances Coming Back in the News  24/7 Wall St.
BioCryst Awarded BCX4430 Advanced Development Contract  MarketWatch
BofA: We're Upgrading Biocryst Pharmaceuticals
In a report published Monday, analysts at Bank of America upgraded BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) to Neutral.
BioCryst Pharmaceuticals Upgraded to "Neutral" at Bank of America ...  Dakota Financial News
Notable Upgrades: Marathon Oil (MRO), BioCryst (BCRX), DexCom (DXCM ...  Wall Street Pit
Buzz Stocks: Charter Communications, Inc., BioCryst Pharmaceuticals, Inc., and ...
... BCRX's 10-day put/call volume ratio of 1.53 rests higher than 90% of all similar readings taken in the past year. Elsewhere, although short interest plunged 17% in the latest reporting period, it still accounts for a lofty 23.9% of BioCryst ...
Top Gainers Pre-Market Trading � Charter Communications, Movado Group ...  FxPips.com
Perilous Reversal Stock: Biocryst Pharmaceuticals (BCRX)
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases.
BioCryst Pharmaceuticals PT Set at $15.00 by Needham & Company LLC (BCRX)  Dakota Financial News
Needham & Company LLC Analysts Give BioCryst Pharmaceuticals a $15.00 ...  sleekmoney
Review on Stocks On The Dive - BioCryst Pharmaceuticals, Inc. (NASDAQ ...
On Monday, Following Stocks were among the �Top 100 Losers� of U.S. Stock Market: BioCryst Pharmaceuticals, Inc.
Yarlagadda S. Babu Sells 12105 Shares of BioCryst Pharmaceuticals Stock ...  WKRB News
Investors Dumping 4 Biotech Stocks - Intrexon (XON), Idera Pharmaceuticals ...  Wall Street Observer
MLV Pounds the Table on BioCryst Pharmaceuticals, Inc.
MLV analyst Vernon Bernardino was out pounding the table on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), reiterating a Buy rating and price target of $15, which represents a potential upside of 85% from where the stock is currently trading.
Earnings Peek: BioCryst Pharmaceuticals Likely To Beat Estimates (BCRX)
BioCryst Pharmaceuticals (NASDAQ:BCRX) is a small biotechnology company with a market cap of $814 million. It develops novel small molecule drugs that block key enzymes involved in orphan and infectious diseases.
BioCryst Pharma (BCRX) Granted Orphan Drug and Fast Track Status from the ...  Wall Street Pit
FDA Grants Fast Track Designation for BCX4161 for the Treatment of ...  GlobeNewswire (press release)
Why BioCryst Pharmaceuticals Inc. Shares Soared
What: Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX ) , a biotechnology company focused on developing small-molecule drugs designed to block enzymes which are vital to the disease development process, spiked higher by as much as 22% after ...
BioCryst Pharmaceuticals Prices Public Offering of Common Stock  GlobeNewswire (press release)
BioCryst Announces Positive Results From OPuS-1, a Phase 2 Trial of BCX4161 ...  MarketWatch
Related articles »  
Stock Analysis on BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)
[Globe Newswire] BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)(TREND ANALYSIS) announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company's development programs at the 14th Annual Needham ...
BioCryst Pharmaceuticals Receives $16.12 Consensus Target Price from ...  Mideast Time
Where is BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Headed?
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule pharmaceuticals that block key enzymes involved in the pathogenesis of diseases.
Related articles »